EuroBiotech: More Articles of Note


> Argenx struck a deal to use Halozyme’s delivery technology to develop subcutaneous formulations of its current and future drug candidates. The biotech paid $30 million (€26 million) upfront to land the deal. Statement 

> Newron Pharmaceuticals completed enrollment in its pivotal Rett syndrome trial. The milestone sets Newron up to deliver top-line results before the end of the year. Release 

> Sotio named Harald Fricke as its CMO. Fricke last worked at Apogenix, a company he co-founded in 2006. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Audion Therapeutics posted phase 1 data on its notch inhibitor in patients with mild to moderate sensorineural hearing loss. A phase 2 trial of the drug started last month. Release  

> BioLineRx priced $15.4 million worth of shares and warrants. Statement

> UniQure dosed the first patient in its pivotal hemophilia B trial. The gene therapy trial is expected to be fully enrolled by the end of the year. Release 

Suggested Articles

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.

A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.

Japanese pharma Daiichi Sankyo is looking to boost its research focus with a series of changes across its R&D.